Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ASH In Review: Roche Refreshes Hematology Portfolio With Robust New Drugs

Executive Summary

Phase II data for antibody-drug conjugate polatuzumab vedotin in diffuse large B cell lymphoma suggest potential for a cure if the drug were given up front, Roche says on investor call after American Society of Hematology meeting.

You may also be interested in...



CEO Interview: Roche Pharma Head Daniel O'Day On R&D Strategy

In an interview with Scrip, Roche Pharma CEO Daniel O'Day emphasized the importance that personalized healthcare will have in transforming R&D and how patients are treated.

CEO Interview: Roche Pharma Head Daniel O'Day On R&D Strategy

In an interview with Scrip, Roche Pharma CEO Daniel O'Day emphasized the importance that personalized healthcare will have in transforming R&D and how patients are treated.

AbbVie, J&J's Imbruvica Has Rare, But Not Surprising Failure In DLBCL

Analysts generally were not surprised that Imbruvica plus R-CHOP did not provide a significant benefit versus R-CHOP alone in a hard-to-treat type of non-Hodgkin lymphoma. The failure leaves an opening for competitors, such as Celgene's Revlimid, which will soon have data in this indication.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100056

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel